Literature DB >> 24796333

Preoperative atrial fibrillation predicts mortality and morbidity after aortic valve replacement.

Tom Kai Ming Wang1, Tharumenthiran Ramanathan2, David Hyun-Min Choi2, Greg Gamble3, Peter Ruygrok4.   

Abstract

OBJECTIVES: Atrial fibrillation (AF) is the commonest cardiac arrhythmia, becoming increasingly prevalent as the population ages. There is conflicting information around whether AF is associated with adverse outcomes after aortic valve replacement (AVR) from the few studies that have investigated this. We compared the characteristics and outcomes of patients undergoing AVR with their history of AF.
METHODS: Isolated AVR patients at Auckland City Hospital 2005-2012 were divided into those with and without preoperative AF for comparative analyses.
RESULTS: Of 620 consecutive patients, 19.2% (119) had permanent or paroxysmal AF preoperatively. Patients with AF were significantly older (70.5 vs 63.4 years, P < 0.001) and were more likely to be New Zealand European (82.4 vs 68.1%, P = 0.004). They also had higher prevalence of NYHA class III-IV (55.4 vs 37.4%, P = 0.004), inpatient operation (62.1 vs 48.3%, P = 0.008), history of stroke (10.9 vs 5.0%, P = 0.031), lower creatinine clearance (73 vs 82, P = 0.001) and higher EuroSCORE II (5.2 vs 3.4%, P < 0.001). Operative mortality (6.7 vs 2.0%, P = 0.012) and composite morbidity (27.7 vs 16.5%, P = 0.006) were also higher in patients with AF. After adjusting for significant variables, preoperative AF remained an independent predictor of operative mortality with an odds ratio of 3.44 (95% confidence interval 1.29-9.13), composite morbidity of 1.79 (1.05-3.04) and a mortality during follow-up hazards ratio of 2.36 (1.44-3.87).
CONCLUSIONS: AF was associated with several cardiovascular and cardiac surgery risk factors, but remained independently associated with short- and long-term mortality. AF should be incorporated into cardiac surgery risk models and surgical AF ablation may be considered with AVR.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Aortic stenosis; Aortic valve replacement; Arrhythmia; Atrial fibrillation; Cardiac surgery

Mesh:

Year:  2014        PMID: 24796333     DOI: 10.1093/icvts/ivu128

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  Patients with Atrial Fibrillation Benefit from SAVR with Surgical Ablation Compared to TAVR Alone.

Authors:  William L Patrick; Zehang Chen; Jason J Han; Benjamin Smood; Akhil Rao; Fabliha Khurshan; Siddharth Yarlagadda; Amit Iyengar; John J Kelly; Joshua C Grimm; Marisa Cevasco; Joseph E Bavaria; Nimesh D Desai
Journal:  Cardiol Ther       Date:  2022-03-31

2.  Type of Atrial Fibrillation and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Aviv A Shaul; Ran Kornowski; Tamir Bental; Hana Vaknin-Assa; Abid Assali; Gregory Golovchiner; Ehud Kadmon; Pablo Codner; Katia Orvin; Boris Strasberg; Alon Barsheshet
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-01-28       Impact factor: 1.468

3.  Preoperative paroxysmal atrial fibrillation predicts high cardiovascular mortality in patients undergoing surgical aortic valve replacement with a bioprosthesis: CAREAVR study.

Authors:  Maunu Nissinen; Joonas Lehto; Fausto Biancari; Tuomo Nieminen; Markus Malmberg; Fredrik Yannopoulos; Samuli Salmi; Juhani K E Airaksinen; Tuomas Kiviniemi; Juha E K Hartikainen
Journal:  Clin Cardiol       Date:  2020-02-05       Impact factor: 2.882

4.  Trends and effect of atrial fibrillation on inpatient outcomes after transcatheter aortic valve replacement.

Authors:  Nikita Patil; Paula D Strassle; Sameer Arora; Chinmay Patel; Kishorbhai Gangani; John P Vavalle
Journal:  Cardiovasc Diagn Ther       Date:  2020-02

5.  Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement.

Authors:  Christina Christersson; Stefan K James; Lars Lindhagen; Anders Ahlsson; Örjan Friberg; Anders Jeppsson; Elisabeth Ståhle
Journal:  Heart       Date:  2019-11-22       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.